[go: up one dir, main page]

BR9812466A - Uso de ifn-alfa e amantadina para o tratamento da hepatite c crÈnica - Google Patents

Uso de ifn-alfa e amantadina para o tratamento da hepatite c crÈnica

Info

Publication number
BR9812466A
BR9812466A BR9812466-8A BR9812466A BR9812466A BR 9812466 A BR9812466 A BR 9812466A BR 9812466 A BR9812466 A BR 9812466A BR 9812466 A BR9812466 A BR 9812466A
Authority
BR
Brazil
Prior art keywords
amantadine
treatment
ifn
chronic hepatitis
alfa
Prior art date
Application number
BR9812466-8A
Other languages
English (en)
Inventor
Friederike Zahm
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9812466A publication Critical patent/BR9812466A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: <B>"USO DE IFN-ALFA E AMANTADINA PARA O TRATAMENTO DA HEPATITE C CRÈNICA''<D>. A presente invenção proporciona o uso de IFN-<244> em associação com Amantadina para a fabricação de medicamentos para o tratamento de infecções por hepatite C crónica. A presente invenção fornece também medicamentos contendo o IFN-<244> e Amantadina como uma preparação combinada para uso simultâneo, separado ou seq³encial na terapia de infecções por hepatite C crónica. A presente invenção fornece ainda um método para o tratamento de infecções por hepatite C crónica em pacientes necessitados de tal tratamento compreendendo a administração de uma quantidade de IFN-<244> em associação com uma quantidade de Amantadina efetiva para tratar a hepatite C.
BR9812466-8A 1997-09-18 1998-09-11 Uso de ifn-alfa e amantadina para o tratamento da hepatite c crÈnica BR9812466A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97116220 1997-09-18
PCT/EP1998/005797 WO1999013894A2 (en) 1997-09-18 1998-09-11 Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c

Publications (1)

Publication Number Publication Date
BR9812466A true BR9812466A (pt) 2000-09-19

Family

ID=8227366

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812466-8A BR9812466A (pt) 1997-09-18 1998-09-11 Uso de ifn-alfa e amantadina para o tratamento da hepatite c crÈnica

Country Status (12)

Country Link
US (1) US20030031647A1 (pt)
EP (1) EP1011714A2 (pt)
JP (1) JP2001516725A (pt)
KR (1) KR100364938B1 (pt)
CN (1) CN1276730A (pt)
AR (1) AR013498A1 (pt)
AU (1) AU746648B2 (pt)
BR (1) BR9812466A (pt)
CA (1) CA2302834A1 (pt)
TR (1) TR200000728T2 (pt)
WO (1) WO1999013894A2 (pt)
ZA (1) ZA988519B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006089066A1 (en) * 2005-02-15 2006-08-24 Neuromolecular Pharmaceuticals, Inc. Combinations therapy for treatment of demyelinating conditions
US8268948B2 (en) * 2006-07-21 2012-09-18 Nektar Therapeutics Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom
WO2010014258A2 (en) * 2008-08-01 2010-02-04 Nektar Therapeutics Al, Corporation Conjugates having a releasable linkage

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
AU5157998A (en) * 1996-11-01 1998-05-29 Thomas Najarian Methods and compositions for treatment of hepatitis c infection
US5849800A (en) * 1997-03-28 1998-12-15 The Penn State Research Foundation Use of amantadine for treatment of Hepatitis C

Also Published As

Publication number Publication date
EP1011714A2 (en) 2000-06-28
US20030031647A1 (en) 2003-02-13
WO1999013894A3 (en) 1999-06-03
AU746648B2 (en) 2002-05-02
KR20010024044A (ko) 2001-03-26
WO1999013894A2 (en) 1999-03-25
JP2001516725A (ja) 2001-10-02
AR013498A1 (es) 2000-12-27
CA2302834A1 (en) 1999-03-25
AU9743098A (en) 1999-04-05
CN1276730A (zh) 2000-12-13
ZA988519B (en) 1999-03-18
TR200000728T2 (tr) 2000-09-21
KR100364938B1 (ko) 2002-12-18

Similar Documents

Publication Publication Date Title
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
BR0009647A (pt) Docetaxel em combinação com rhumab her2 para o tratamento de cânceres
BR0209365A (pt) Usos farmacêuticos de bisfosfonatos
BR9812484A (pt) Terapia combinada para erradicação de hcv-rna detectável em pacientes com infecção crÈnica por hepatite c
DE69533112D1 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
IL134345A0 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
DE69434121D1 (de) Pharmazeutische zusammensetzung zur immunstimulierenden therapie
BR0115162A (pt) Tratamentos antitumorais eficazes
BR9808100A (pt) Utilização de amandantina para tratamento de hepatite c.
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
BR9911917A (pt) Composições compreendendo análogos de gaba e cafeìna
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
ATE372774T1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
BR0017329A (pt) Formulção farmacêutica de um medicamento, uso de melatonina na fabricação de um medicamento, e, método para prevenção ou tratamento de sintomas de discinesia tardia em um paciente usanto tal medicamento
BR9908716A (pt) Tratamento de disfunção sexual em certos grupos de pacientes
BR9812466A (pt) Uso de ifn-alfa e amantadina para o tratamento da hepatite c crÈnica
KR960700734A (ko) 사람 암에 대한 시스플래틴/타목시펜 배합 치료(Combination cisplatin/tamoxifen therapy for human cancers)
PT1007085E (pt) Utilizacao da hormona de crescimento em composicoes para o tratamento da resistencia a insulina no coracao
BR0113115A (pt) Tratamento de hepatite c com timosina, interferon e ribavirina
BR9801839A (pt) Medicamento analgésico e aplicação de (+) -0-demetiltramadol.
BR0116373A (pt) Utilização de tienilciclo-hexilamina, produto, e, composições farmacêuticas

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7O, 8O E 9O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1909 DE 07/08/2007.